Lannett Co Inc (LCI) Receives Analyst Rating

Lannett Co Inc (LCI) : Zacks Investment Research ranks Lannett Co Inc (LCI) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 2, which indicates as a Buy.

Lannett Co Inc (LCI) : The highest level Lannett Co Inc (LCI) is projected to reach is $49 for the short term and the lowest estimate is at $32. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $41 and the possibility the share price can swing is $7.07.


Also, In the latest statement by the brokerage house, Raymond James maintains its outlook on Lannett Co Inc (NYSE:LCI). The current rating of the shares is Outperform, according to the research report released by the firm. The brokerage firm raises the price target from $31 per share to $43 per share. The rating by the firm was issued on August 24, 2016.

Lannett Co Inc (NYSE:LCI): After opening at $31.95, the stock dipped to an intraday low of $31.46 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $32.52 and the buying power remained strong till the end. The stock closed at $32.38 for the day, a gain of 1.79% for the day session. The total traded volume was 608,856. The stocks close on the previous trading day was $31.81.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Companys products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital products, Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with around 12 varying potencies. Digoxin tablets are produced and marketed with approximately two different potencies. It distributes around three products containing Butalbital. Ursodiol capsules are produced and marketed in 300 milligram capsules. The Company offers a range of pain management products, such as Cocaine Topical Solution (C-Topical), Morphine Sulfate Oral Solution, Hydromorphone hydrochloric acid (HCl) tablets and Codeine Sulfate tablets.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.